Vyome Holdings announces positive interim data from VT-1953 Phase 2 study

Vyome Holdings (HIND) announced positive interim results from its investigator-initiated Phase 2 study of VT-1953 topical gel in patients with malignant fungating wounds. The interim results showed the treatment significantly reduced MFW-associated malodor, which was the primary endpoint. Patients also reported significant improvements in lesion pain and quality of life. No clinically significant adverse trends were noted. The company anticipates interacting with the FDA in early 2026.